gamma-l-Glutamyl-l-valine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: gamma-l-Glutamyl-l-valine
• 英文别名: 2-amino-5-[(1-carboxy-2-methylpropyl)amino]-5-oxopentanoic acid
• 化学式: C₁₀H₁₈N₂O₅
• 分子量: 246.26
• InChiKey: AQAKHZVPOOGUCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  130
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• METHOD FOR PRODUCING GAMMA -GLUTAMYL-VALYL-GLYCINE CRYSTAL
  申请人：AJINOMOTO CO., INC.

  公开号：US20150361133A1

  公开（公告）日：2015-12-17

  The present invention provides a method for efficiently producing a γ-glutamyl-valyl-glycine crystal. Specifically, the present invention provides a method for producing a γ-glutamyl-valyl-glycine crystal, which includes the steps of: preparing a mixed solution of valyl-glycine or a salt thereof and γ-glutamyl-valyl-glycine, wherein the mixed solution contains valyl-glycine or the salt thereof in an amount of 20 mass % or more relative to the mass of γ-glutamyl-valyl-glycine; adjusting the amount of valyl-glycine or the salt thereof in the prepared mixed solution to 0.1 mass % or more and less than 20 mass % relative to the mass of γ-glutamyl-valyl-glycine to prepare a γ-glutamyl-valyl-glycine solution; and subjecting the γ-glutamyl-valyl-glycine solution to a crystallization procedure to produce the γ-glutamyl-valyl-glycine crystal.

  本发明提供了一种高效生产γ-谷氨酰-缬氨酸-甘氨酸晶体的方法。具体来说，本发明提供了一种生产γ-谷氨酰-缬氨酸-甘氨酸晶体的方法，包括以下步骤：制备缬氨酸-甘氨酸或其盐和γ-谷氨酰-缬氨酸的混合溶液，其中混合溶液中缬氨酸或其盐的质量占γ-谷氨酰-缬氨酸质量的20%或以上；调整制备的混合溶液中缬氨酸或其盐的量，使其相对于γ-谷氨酰-缬氨酸的质量为0.1%或以上但小于20%；将γ-谷氨酰-缬氨酸溶液经过结晶程序进行结晶，生产γ-谷氨酰-缬氨酸晶体。
• ALKYLAMINE DERIVATIVE
  申请人：SUGIKI Masayuki

  公开号：US20130237702A1

  公开（公告）日：2013-09-12

  A composition containing a compound represented by General Formula (I) below (see the definition in the specification for the symbols in the formula) or a salt thereof has an excellent CaSR agonistic effect and provides a pharmaceutical agent, a CaSR agonistic agent, a prophylactic or therapeutic agent for a disease that can be ameliorated through CaSR activation as well as seasonings and an agent for imparting kokumi.

  含有下面普通公式（I）所代表的化合物（请参见规范中公式中符号的定义）或其盐的组合物具有出色的CaSR激动作用，并提供了药物制剂、CaSR激动剂、预防或治疗可以通过CaSR激活改善的疾病的制剂，以及调味料和赋予kokumi的剂。
• METHOD FOR PRODUCING -GLUTAMYL-VALYL-GLYCINE CRYSTAL
  申请人：Ajinomoto Co., Inc.

  公开号：EP2883960A1

  公开（公告）日：2015-06-17

  The present invention provides a method for efficiently producing a γ-glutamyl-valyl-glycine crystal. Specifically, the present invention provides a method for producing a γ-glutamyl-valyl-glycine crystal, which includes the steps of: preparing a mixed solution of valyl-glycine or a salt thereof and γ-glutamyl-valyl-glycine, wherein the mixed solution contains valyl-glycine or the salt thereof in an amount of 20 mass% or more relative to the mass of γ-glutamyl-valyl-glycine; adjusting the amount of valyl-glycine or the salt thereof in the prepared mixed solution to 0.1 mass% or more and less than 20 mass% relative to the mass of γ-glutamyl-valyl-glycine to prepare a γ-glutamyl-valyl-glycine solution; and subjecting the γ-glutamyl-valyl-glycine solution to a crystallization procedure to produce the γ-glutamyl-valyl-glycine crystal.

  本发明提供了一种高效生产γ-谷氨酰-缬氨酰-甘氨酸晶体的方法。具体来说，本发明提供了一种生产γ-谷氨酰-缬氨酰-甘氨酸晶体的方法，该方法包括以下步骤：制备缬氨酰-甘氨酸或其盐和γ-谷氨酰-缬氨酰-甘氨酸的混合溶液，其中混合溶液中缬氨酰-甘氨酸或其盐的含量相对于γ-谷氨酰-缬氨酰-甘氨酸的质量大于等于 20 质量％；将制备的混合溶液中缬氨酰-甘氨酸或其盐的含量调整为 0.1 质量％或更多，但相对于 γ-谷氨酰-缬氨酰-甘氨酸的质量小于 20 质量％，以制备 γ-谷氨酰-缬氨酰-甘氨酸溶液；并将 γ-谷氨酰-缬氨酰-甘氨酸溶液进行结晶处理，以生成 γ-谷氨酰-缬氨酰-甘氨酸晶体。
• TRYPTOPHAN AS A BIOMARKERS FOR KIDNEY FUNCTION AND METHODS USING THE SAME
  申请人：Metabolon, Inc.

  公开号：EP3410115A1

  公开（公告）日：2018-12-05

  Biomarkers of kidney function and methods for using said biomarkers for assessing kidney function, monitoring kidney function, diagnosing acute kidney injury, and diagnosing chronic kidney disease are provided. Also provided are suites of small molecule entities as biomarkers for chronic kidney disease.

  本研究提供了肾功能生物标志物以及使用上述生物标志物评估肾功能、监测肾功能、诊断急性肾损伤和诊断慢性肾病的方法。此外，还提供了作为慢性肾病生物标志物的小分子实体套件。
• Methods and systems for determining autism spectrum disorder risk
  申请人：Laboratory Corporation of America Holdings

  公开号：US10041932B2

  公开（公告）日：2018-08-07

  In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.

  在某些实施方案中，本发明源于发现血液中代谢物水平的群体分布曲线分析可用于促进预测自闭症谱系障碍（ASD）的风险和/或区分受试者的自闭症谱系障碍和非自闭症谱系障碍发育迟缓（DD）。在某些方面，评估代谢物分布曲线中尾部效应的存在、不存在和/或方向（上部或下部）的信息可用于预测 ASD 的风险和/或区分 ASD 和 DD。